M
Mark Hallett
Researcher at National Institutes of Health
Publications - 1234
Citations - 136876
Mark Hallett is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Transcranial magnetic stimulation & Motor cortex. The author has an hindex of 186, co-authored 1170 publications receiving 123741 citations. Previous affiliations of Mark Hallett include Government of the United States of America & Armed Forces Institute of Pathology.
Papers
More filters
Journal ArticleDOI
Changes in spinal excitability after PAS.
TL;DR: It is demonstrated that PAS induces parallel changes in cortical and spinal excitability, and here, instead of F waves, H reflex recruitment curves are used to assess spinalexcitability.
Journal ArticleDOI
Tetracycline fluorescence as calcium-probe for nerve membrane with some model studies using erythrocyte ghosts
TL;DR: Both squid giant axons and lobster nerves, stained internally and externally, show a small increase in fluorescent light during the action potential and chlorotetracycline may be monitoring calcium concentration associated with the inner surface of the nerve membrane.
Journal ArticleDOI
Impaired sense of agency in functional movement disorders: An fMRI study.
TL;DR: The authors found selective dysfunction of the SA neural network, whereby the dorsolateral prefrontal cortex and pre-supplementary motor area on the right did not respond differentially to the loss of movement control.
Journal ArticleDOI
Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis.
TL;DR: Six patients with severe postural cerebellar tremor were studied in a double-blind, placebo-controlled, crossover trial with isoniazid, finding a definite, but limited, therapeutic role for the drug.
Journal ArticleDOI
Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.
TL;DR: In this paper, the authors explored the efficacy and safety of BoNT treatment for FHD, but none have followed a large number of patients for 10 or more years, and none have evaluated the safety of the treatment.